New KIR-CAR T cell therapy shows promise in multiple solid cancers

CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...

BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering multiple myeloma

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...
Targeted Oncology

Expanding CAR T-Cell Therapy in Community Oncology: A Critical Next Step for Access

Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...
IFLScience on MSN

CAR-T therapy is revolutionizing cancer treatment. Next on the list: autoimmune disease

A woman who had been sick for many years with three autoimmune conditions has experienced a remarkable recovery after being ...
Healio

FDA to ‘carefully shepherd’ CAR T-cell therapy trials in autoimmune, rheumatic disease

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...
Fierce Biotech

In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...
The American Journal of Managed Care

CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
Everyday Health

What to Expect When Starting CAR T-Cell Therapy for Large B-Cell Lymphoma

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
Stocktwits on MSN

Eli Lilly bolsters CAR T-cell immunotherapy pipeline with Kelonia acquisition – and it’s paying $7B

Kelonia shareholders will receive up to $7 billion, including $3.25 billion upfront, with additional payments tied to ...
Fred Hutch

Understanding Parkinsonism after CAR T therapy

Doctors at the University of Washington and Fred Hutch Cancer Center have better characterized an emerging complication of chimeric antigen receptor (CAR) T-cell therapy. A recent paper in Movement ...